Chronic infection of hepatitis B virus (HBV) presents one of the serious public health challenges worldwide. Current treatment of chronic hepatitis B (CHB) is limited, and is composed of interferon and nucleoside/nucleotide reverse transcriptase inhibitors (NRTI). Interferon is poorly tolerated and is only responsive in a small fraction of CHB patients and NRTIs often face the problem of emergence of drug resistance during long-term treatment. The current treatment of CHB can be improved in several ways including genotyping mutations associated with drug resistance before treatment to guide the choice of NRTIs and suitable combinations among NRTIs and interferon. It is important to continue research in the identification of novel therapeutic targets in the life cycle of HBV or in the host immune system to stimulate the development of new antiviral agents and immunotherapies. Several antiviral agents targeting HBV entry, cccDNA, capsid formation, viral morphogenesis and virion secretion, as well as two therapeutic vaccines are currently being evaluated in preclinical studies or in clinical trials to assess their anti-HBV efficacy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Block T M, Lu X, Mehta A S, et al. 1998. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med, 4:610–614.
Chotiyaputta W, Lok A. 2009. hepatitis B virus variants. Nat Rev Gastroenterol Hepatol, 6: 453–462.
Delaney W E 4th, Edwards R, Colledge D, et al. 2002. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother, 46: 3057–3060.
Deng Q, Zhai J W, Michel M L, et al. 2007. Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. J Virol, 81: 4244–4254.
Deres K, Schroder C H, Paessens A, et al. 2003. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science, 299: 893–896.
Dienstag J L. 2008. Hepatitis B virus infection. N Engl J Med, 359:1486–1500.
Ganem D, Prince A M. 2004. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med, 350:1118–1129.
Glebe D, Urban S, Knoop E V, et al. 2005. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology, 129: 234–245.
Gripon P, Cannie I, Urban S. 2005. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol, 79: 1613–1622.
King R W, Ladner S K, Miller T J, et al. 1998. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (−)β-L-2’,3’-dideoxy-3’-thiacytidine. Antimicrob Agents Chemother, 42: 3179–3186.
Lampertico P. Viganò M, Manenti E, et al. 2007. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology, 133: 1445–1451.
Lazar C, Durantel D, Macovei A, et al. 2007. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res, 76: 30–37.
Lucifora J, Durantel D, Testoni B, et al. 2010. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology, 51: 63–72.
Mancini-Bourgine M, Fontaine H, Bréchot C, et al. 2006. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine, 24: 4482–4489.
Mehta A, Carrouée S, Conyers B, et al. 2001. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology, 33: 1488–1495.
Perrillo R. 2009. Benefits and risks of interferon therapy for hepatitis B. Hepatology, 49: S103–111.
Petersen J, Dandri M, Mier W, et al. 2008. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol, 26: 335–341.
Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev Immunol, 5: 215–229.
Riordan S M, Skinner N, Kurtovic J, et al. 2006. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol, 13: 972–974.
Seeger C, Mason W S. 2005. Hepatitis B virus biology. Microbiol Mol Biol Rev, 2000, 64: 51–68.
Shepard C W, Simard E P, Finelli L, et al. 2006. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev, 28: 112–125.
Thompson A J, Colledge D, Rodgers S, et al. 2009. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther, 14: 797–808.
Vincent I E, Lucifora J, Durantel D, et al. 2009. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antivir Ther, 14: 131–135.
Weber O, Schlemmer K H, Hartmann E, et al. 2002. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res, 54: 69–78.
Xu D Z, Zhao K, Guo L M, et al. 2008. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One, 3: e2565.
Yao X, Zheng B, Zhou J, et al. 2007. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine, 25: 1771–1779.
Zimmerman K A, Fischer K P, Joyce M A, et al. 2008. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol, 82: 8013–8021.
Foundation items: This work was supported by “973” project (2005CB522902), Grand Science and Technology Special Project (2008ZX10002-010, 015) and Shanghai Municipal Government (8410706800).
About this article
Cite this article
Xie, Yh., Hong, R., Liu, W. et al. Development of novel therapeutics for chronic hepatitis B. Virol. Sin. 25, 294–300 (2010). https://doi.org/10.1007/s12250-010-3138-9
- Hepatitis B virus (HBV)
- Chronic infection